In Devices, the Market for Mid-Caps Remains Strong
Executive SummaryWhile investors and big company acquirers still seem wary of small device companies, two recent deals--Guidant's acquisition of CardioThoracic Systems and Medtronic's purchase of Xomed, suggest that large device companies will still pay handsomely for companies with established businesses.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.